Features
Novo’s oral Wegovy showed what happens when a needle-bound peptide becomes a pill. Entera Bio has been building the same type of breakthrough in osteoporosis - a vast, underserved market with no oral anabolic competition and a stock still valued like few are watching.
Wall Street Wire
Duke's incoming CEO, Yiftach Kleinman, spent more than a decade at the maker of the Iron Dome and Trophy system, then scaled a loitering-munitions startup into a buyout. Now he is stepping in to lead a freshly Nasdaq-listed drone firm that is leaning harder into defense.
Features
Medicare’s skin-substitute reset has rattled wound care, but MediWound may sit on the right side of the shock. Its late-stage biologic, EscharEx, offers differentiated upside in a category suddenly hungry for safer, drug-like assets.
Features
Alpha Tau’s Tolmar partnership adds capital, commercial muscle, and fresh validation for Alpha DaRT. With prostate, pancreatic, skin-cancer, and glioblastoma catalysts advancing, the small-cap oncology story is gaining momentum.
Features
Peptides are everywhere - but Entera Bio is aiming beyond the hype: turning proven injectable therapies into oral tablets, with EB613 headed toward Phase 3 as a potential first-in-class bone-building pill for osteoporosis.
Wall Street Wire
The Trump administration is reportedly in talks to fund U.S. drone manufacturers through the Pentagon's Office of Strategic Capital - a vehicle set for an approximately 1,247% funding increase in fiscal 2027 - while Section 1709 of the FY25 NDAA reshapes the domestic drone supply chain through the
Features
QTREX, the new name in quantum, is building into the cryogenic bottleneck holding back the entire field | NASDAQ: QTEX*
Features
Nasus Pharma is betting it can reinvent emergency allergy treatment with a needle-free epinephrine nasal spray - and after strong Phase II data and a new $19 Zacks price target, Wall Street may be starting to pay attention | NYSE: NSRX*